期刊文献+

氨磺必利与利培酮治疗伴抑郁症状的精神分裂症对照研究 被引量:20

A control study of amisulpride vs. risperidone in the treatment of schizophrenia with depressive symptoms
下载PDF
导出
摘要 目的探讨氨磺必利治疗合并抑郁症状的精神分裂症患者的临床疗效。方法将60例合并抑郁症状的精神分裂症患者随机分为观察组和对照组各30例,观察组采用氨磺必利治疗,对照组采用利培酮治疗,采用阳性和阴性综合征量表(PANSS)、汉密尔顿抑郁量表(HAMD)和治疗中需处理的不良反应症状量表(TESS)比较两组的疗效及不良反应。结果治疗后观察组PANSS阴性症状减分和HAMD减分均大于对照组(P<0.05);观察组总有效率高于对照组(P<0.05)。观察组总不良反应发生率低于对照组(P<0.05)。结论氨磺必利能显著缓解精神分裂症患者的阴性症状,同时降低抑郁程度,且不良反应少。 Objective To explore the efficiency of amisulpride in the treatment of schizophrenia with depressive symptoms.Methods 60 schizophrenic patients with depressive symptoms were randomized into study group( 30 cases) treated with amisulpride and control group( 30 cases) treated with risperidone for 8 weeks. All patients were assessed with Positive and Negative Syndrome Scale( PANSS),Hamilton Depression Scale( HAMD) and Treatment Emergent Symptom Scale( TESS) at baseline and at the end of the treatment. Result Reductions of factor score of negative symptoms in PANSS and HAMD in study group were significantly higher than those in control group( P〈0. 05). Effective rate was significantly higher in study group than that in control group( P〈0. 05). Incidence rate of side effects was significantly lower in study group than that in control group( P〈0. 05). Conclusion Amisulpride can improve effectively negative symptoms and depressive symptoms of schizophrenia with less adverse reactions.
出处 《精神医学杂志》 2016年第4期277-279,共3页 Journal of Psychiatry
关键词 氨磺必利 抑郁 精神分裂症 疗效 Amisulpride Depressive symptom Schizophrenia Efficiency
  • 相关文献

参考文献14

二级参考文献103

  • 1吴仁容,李乐华.新型抗精神病药:阿立哌唑[J].国外医学(精神病学分册),2004,31(3):177-179. 被引量:380
  • 2石玉中,张红星,陈全花,吕路线.精神分裂症后抑郁及心理干预(英文)[J].神经疾病与精神卫生,2006,6(3):223-224. 被引量:4
  • 3沈渔邨.精神病学[M].5版.北京:人民卫生出版社.2009:838.
  • 4Stahl SM. Dopamine system stabiliaers, aripiprazole and the nextgeneration of antipsychotics,party2 . illustrating theirmechanism ofaction. J Clin Psychiatry,2001,62(12) :923-924.
  • 5Scatton B,Claustre Y,Cudennec A,et al. Amisulpride:from animalpharmacology to therapeutic action. Int Clin Psychopharmacol,1997,12(2) :29-36.
  • 6McKeage K,Plosker G L.Amisulpride,A review of its use in themanagement of schizophrenia[J].CNS Drugs,2004,18(13):933-956.
  • 7Hwang T J,Lee S M,Sun H J,et al.Amisulpride versus risperidonein the treatment of schizophrenic patients:A double-blind pilotstudy in Taiwan[J].J Formos Med Assoc,2003,102(1):30-36.
  • 8Lieberman J A,Phillips M,Gu H,et al.Atypical and conventionalantipsychotic drugs in treatment-naive first-episodeschizophrenia:A 52-week randomized trial of clozapine vschlorpromazine[J].Neuropsychopharmacology,2003,28(5):995-1003.
  • 9Xiberas X,Martinot J L,Mallet L,et al.In vivoertrastriatal andstriatal D2 dopamine receptor blockade by amisulpride inschizophrenia[J].J Chin Psychophramacol,2001(21):207-214.
  • 10Burns T,Bale R.Clinical advantages of amisulpride in the treatmentof acute schizophrenia[J].J Int Med Res,2001,29(6):451-466.

共引文献113

同被引文献153

引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部